Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by AGP Franklin LLC

Key Points

• AGP Franklin LLC significantly increased its holdings in Teva Pharmaceutical Industries by 932.2% in the first quarter, now owning 124,468 shares worth approximately $1.91 million.
• Teva's recent quarterly earnings report showed an EPS of $0.52, exceeding analysts' expectations, despite a negative net margin of 7.74%.
• Several research firms have upgraded Teva's stock, with the consensus rating currently at "Buy" and a target price around $24.71.

AGP Franklin LLC grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 932.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,468 shares of the company's stock after acquiring an additional 112,410 shares during the period. AGP Franklin LLC's holdings in Teva Pharmaceutical Industries were worth $1,913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of TEVA. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $29,000. Golden State Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $44,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth $54,000. Finally, Versant Capital Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after purchasing an additional 4,312 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $1.17 on Thursday, reaching $15.67. 12,574,627 shares of the stock were exchanged, compared to its average volume of 12,154,457. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The business has a fifty day moving average price of $16.92 and a two-hundred day moving average price of $16.70. The firm has a market capitalization of $17.97 billion, a PE ratio of -13.62, a PEG ratio of 0.98 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period in the previous year, the business posted $0.61 earnings per share. The business's revenue was up .3% compared to the same quarter last year. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.49% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TEVA. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.